Trinomia cardiovascular polypill real world results
A multicentre real world clinical trial of Trinomia the cardiovascular polypill containing aspirin, atorvastatin and ramipril reports major improvements on cardiovascular risk factors. The SORS study followed approximately 1200 people with cardiovascular issues for a period of 1 year. All of the participants took a single Trinomia pill daily.
At the end of 1 year blood pressure was significantly reduced, ‘bad’ cholesterol levels were significantly reduced. Together these results led to a major reduction in cardiovascular risk scores. Interestingly these first real world clinical outcomes of Trinomia are above and beyond those within randomised controlled trials. In real world a single polypill appears to make a significant difference to not only adherence but also cardiovascular risk.
New Zealand has a large issue when it comes to cardiovascular disease, it is our largest killer accounting for 33% of all deaths. Currently 180,000 New Zealanders are living with cardiovascular disease which includes heart, stroke and blood vessel disease.
A previous New Zealand study has shown that a cardiovascular polypill can also help to reduce health inequity (available here). Equity is one of the Government’s priorities for health: Ministry of Health – What we do 2018
For more information:
Trinomia (aspirin, atorvastatin, ramipril) product information